Project Grant R01CA309463
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $949K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
- The National Cancer Institute awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $179,403 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine longitudinal effects of nicotine pouch use on tobacco use behaviors, biomarkers, and nicotine dependence among U.S. adults. The research will harmonize nationally representative population assessment data from the PATH (Population...
- The National Cancer Institute of the National Institutes of Health awarded the University of Southern California $426,828 on July 6, 2026, through the Cancer Cause and Prevention Research program (CFDA 93.393) to test regulatory strategies promoting e-cigarette cessation among young adults. The University of Southern California will conduct a study using a simulated vape shop experimental laboratory space ("The Puff Point") to evaluate two innovative policy interventions designed to...
- The National Institutes of Health National Cancer Institute awarded The Medical University of South Carolina $586,018 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a three-arm clinical trial testing augmented doses of nicotine replacement therapy for individuals who use both combustible cigarettes and e-cigarettes and wish to quit both products. The trial will randomize dual-use participants to receive behavioral support combined with...
- The National Institute on Drug Abuse awarded the Board of Regents of the University of Nebraska $422,125 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to examine oral nicotine pouch use and health effects among adolescents and young adults. The recipient, through its University of Nebraska Medical Center division in Omaha, Nebraska, will harmonize nationally representative population assessment data from the PATH Study waves 7–9 (2022–2025) to investigate oral...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded the University of Alabama a Project Grant of $2,524,071 on September 23, 2025, for research investigating the neurocomputational mechanisms underlying self-regulation and reinforcement learning in smoking cessation decisions. The four-year project, with completion scheduled for August 31, 2029, will employ computational model-based multimodal neuroimaging...
- The National Institutes of Health National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $694,182 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a prospective longitudinal cohort study examining biomarker levels and respiratory health effects associated with exposure to electronic cigarettes and combustible cigarettes in young children. The research enrolls 300 children ages 1 to 10 years across three equal exposure...
- The National Cancer Institute, within the Department of Health and Human Services, awarded the University of Oklahoma Health Sciences Center $606,142 on August 1, 2026, to conduct a fully powered randomized controlled trial testing a novel mobile messaging intervention designed to increase smoking quit attempts and cessation among adults who initially report not being ready to quit smoking within thirty days. The intervention, called PHOENIX, delivers daily text messages tailored to...
- The National Cancer Institute awarded the Regents of the University of Minnesota $621,549 under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 1, 2026. The award funds a randomized experimental marketplace study evaluating nicotine pouches as a potential substitute for combustible menthol cigarettes in the context of menthol flavor bans. The research specifically examines the acceptability of nicotine pouches relative to medicinal nicotine among menthol cigarette smokers,...
- The National Cancer Institute awarded the University of Virginia $669,910 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to optimize pharmacist-led tobacco treatment for individuals who smoke and are not ready to make a quit attempt in federally qualified health centers. The project, titled "Optimizing Pharmacist-Led Tobacco Treatment for Individuals Who Smoke and Are Not Ready to Make a Quit Attempt in Federally Qualified Health Centers,"...
- The National Cancer Institute awarded the University of Rochester $583,304 on August 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate toxicological assessment of emerging nicotine analogs in electronic nicotine delivery systems (ENDS). The research addresses a substantial knowledge gap regarding the safety profile of novel nicotine analogs, including 6-methyl nicotine and nicotinamide, which manufacturers have introduced to circumvent premarket...